All
  • All
  • Insight
  • Research Services
  • Preclinical CRO
  • Animal Resource Bank
CN
中文 English

Hypertension HT animal model

Hypertension HT animal model

Explore more

Hypertension
Psychiatric & neurological disease models

On this page

Model Introduction

Model Introduction

Platform Service Advantages

Platform Service Advantages

Experimental results

Experimental results

Publish an article

View more

Hypertension

Introduction to the HT Animal Model

Animal models of hypertension (HT) can be established through various approaches, including surgical procedures, pharmacological agents, high-salt diets, and genetic engineering, thereby mimicking both primary and secondary forms of human hypertension. Following model induction, animals exhibit sustained elevations in blood pressure; prolonged hypertensive states progressively lead to vascular remodeling, cardiac hypertrophy, ventricular remodeling, renal injury, cerebrovascular lesions, and other multiorgan complications, fully recapitulating the pathological progression of clinical hypertension and target‑organ damage. These models reliably reproduce hallmark phenotypes such as elevated blood pressure, reduced vascular elasticity, and impaired target‑organ function, making them widely applicable for investigating the pathogenic mechanisms of hypertension, screening antihypertensive drugs, evaluating drug efficacy, and studying hypertension‑related complications.

Advantages of Aniphe BioLab’s HT Mouse Model Platform Services

This platform can establish a variety of hypertension animal models; its modeling techniques are well‑established, and its assay systems are robust, thereby meeting the needs of diverse research studies and drug development.

Comprehensive model coverage

Strong modeling stability

The protocol is well-established, with sustained and stable increases in animal blood pressure, a high success rate in establishing the model, and excellent experimental reproducibility.

Standardization of the modeling process

End-to-end standardized quality control

Standardized feeding and procedures, regular blood pressure monitoring, and complete, traceable experimental data.

Multidimensional Evaluation System

Comprehensive testing methods

Supports ambulatory blood pressure monitoring, imaging, pathology, and molecular biomarker assays to assess multi-organ damage.

Adaptable to multi-cycle studies

Customizable solutions

It can flexibly adjust the modeling cycle and intervention protocols to accommodate diverse experimental designs.

Standardization of Data Delivery

One-stop service

The entire process is handled independently, ensuring efficient delivery, and we are capable of undertaking both basic research and regulatory‑compliant submission projects.

Modeling cycle

4–10 weeks

1  Laboratory animals

Dogs, rabbits, rats

1  Positive drug

Common antihypertensive agents such as losartan, amlodipine, valsartan, and metoprolol are used as positive controls and can effectively regulate blood pressure and mitigate target-organ damage.

1  Application areas

It is primarily used to investigate the pathogenic mechanisms underlying blood pressure regulation, vascular remodeling, and organ injury; to screen antihypertensive agents and drugs for the prevention and treatment of hypertensive complications, and to evaluate their pharmacodynamics and safety; and it can also be applied to identifying drug targets and developing natural bioactive compounds, thereby providing comprehensive support for basic biomedical research and preclinical development activities such as Investigational New Drug (IND) submissions.

Experimental results

Construction of HT animal models

SHR rat model: Spontaneously hypertensive rats, which require no artificial induction of hypertension, exhibit a gradual increase in blood pressure with age, thereby mimicking essential hypertension.

Renovascular hypertension model: Surgical renal artery stenosis activates the pressor pathway, inducing sustained hypertension and thereby mimicking secondary renovascular hypertension.

Model features: Within a specified time frame, the rate of increase in arterial blood pressure in animals is directly proportional to the degree of arterial stenosis. The procedure is simple, hypertension remains stable, and the pathophysiological features closely resemble those of human hypertension; moreover, the response to antihypertensive agents is consistent with that observed in hypertensive patients, making this model suitable for drug screening and efficacy evaluation.

 

Losartan treatment data

01 Ambulatory Blood Pressure Monitoring Results

Losartan significantly reduces systolic blood pressure in spontaneously hypertensive rats and serves as an effective positive control drug in the SHR hypertension model.

 

 

In SHR rats, the endothelium-dependent and endothelium-independent vasodilatory functions, as well as the vasodilatory sensitivity (pD₂), were all significantly impaired. Losartan treatment markedly enhanced the vascular responses to acetylcholine and sodium nitroprusside, restored endothelial–smooth muscle–mediated vasodilation, and had no significant effect on vascular relaxation in normotensive WKY rats.

 

 

02 HE Staining Results

Histopathological analysis with hematoxylin–eosin staining revealed that the mesenteric third-order arteries in WKY rats exhibited a normal architecture. In SHR rats, the vascular walls were markedly thickened and the lumina were narrowed; following treatment with losartan, both vascular hypertrophy and luminal stenosis were significantly alleviated, suggesting that losartan can reverse hypertension‑induced remodeling of resistance vessels.

 

References: The effects of losartan intervention during the prehypertensive stage on resistance vessel remodeling and angiotensin II type 1 receptor expression in adult spontaneously hypertensive rats.